Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

G. Curigliano, M. De Laurentiis, N. Harbeck, S. Kuemmel, J.Á. García-Sáenz, R. Sanchez Bayona, D. Rea, A. Okines, B. Pistilli, E. Sears, J. Maitland, S. Kloss, T. Wasserman, M. Ignatiadis

Open source

DOI
10.1016/j.esmoop.2026.108535
Published
2026-10
Container
ESMO Open
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.108535,
  title = {Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting},
  author = {G. Curigliano and M. De Laurentiis and N. Harbeck and S. Kuemmel and J.Á. García-Sáenz and R. Sanchez Bayona and D. Rea and A. Okines and B. Pistilli and E. Sears and J. Maitland and S. Kloss and T. Wasserman and M. Ignatiadis},
  year = {2026},
  journal = {ESMO Open},
  doi = {10.1016/j.esmoop.2026.108535},
  url = {https://doi.org/10.1016/j.esmoop.2026.108535}
}

RIS

TY  - JOUR
TI  - Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting
AU  - G. Curigliano
AU  - M. De Laurentiis
AU  - N. Harbeck
AU  - S. Kuemmel
AU  - J.Á. García-Sáenz
AU  - R. Sanchez Bayona
AU  - D. Rea
AU  - A. Okines
AU  - B. Pistilli
AU  - E. Sears
AU  - J. Maitland
AU  - S. Kloss
AU  - T. Wasserman
AU  - M. Ignatiadis
PY  - 2026
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2026.108535
UR  - https://doi.org/10.1016/j.esmoop.2026.108535
ER  - 

APA

Curigliano, G., Laurentiis, M. D., Harbeck, N., Kuemmel, S., García-Sáenz, J., Bayona, R. S., Rea, D., Okines, A., Pistilli, B., Sears, E., Maitland, J., Kloss, S., Wasserman, T., & Ignatiadis, M. (2026). Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108535

Source records